Vericel (VCEL) to Release Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $64.5680 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. The business had revenue of $63.24 million during the quarter, compared to analysts’ expectations of $64.61 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The business’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.10) earnings per share. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vericel Stock Performance

Shares of Vericel stock opened at $34.88 on Thursday. The stock has a market capitalization of $1.76 billion, a PE ratio of 290.69 and a beta of 1.39. Vericel has a 52-week low of $29.24 and a 52-week high of $63.00. The company has a 50-day simple moving average of $33.69 and a two-hundred day simple moving average of $37.92.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on VCEL shares. Truist Financial decreased their target price on shares of Vericel from $46.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Canaccord Genuity Group decreased their price objective on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Vericel in a report on Wednesday, October 8th. BTIG Research cut shares of Vericel from a “buy” rating to a “neutral” rating in a report on Wednesday, September 17th. Finally, Zacks Research raised shares of Vericel from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vericel presently has an average rating of “Moderate Buy” and an average target price of $58.40.

Institutional Trading of Vericel

Several large investors have recently added to or reduced their stakes in VCEL. Osaic Holdings Inc. grew its position in Vericel by 13.7% during the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 353 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Vericel by 178.4% in the second quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 2,077 shares during the period. Connecticut Wealth Management LLC bought a new position in shares of Vericel in the second quarter worth approximately $201,000. Tower Research Capital LLC TRC boosted its position in shares of Vericel by 7,627.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,791 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 4,729 shares during the period. Finally, E Fund Management Co. Ltd. bought a new position in shares of Vericel in the second quarter worth approximately $225,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.